Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

OnCore Login
Login to Oncore Network

Login to Oncore Network

Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

Current Trials

BRE12-158

A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients with Triple Negative Breast Cancer.

Status: Open to Accrual
Read More

GI14-198

Phase II Randomized, Double-Blind Study of mFOLFIRINOX Plus Ramucirumab versus mFOLFIRINOX plus placebo in Advanced Pancreatic Cancer Patients

Status: Open to Accrual
Read More

GI15-225

This is an open-label, multi-center pilot study designed to evaluate the efficacy as well as the safety of combining pembrolizumab with Yttrium-90 (Y90) radioembolization in subjects with poor prognosis (high-risk) hepatocellular carcinoma who are not eligible for liver transplant or surgical resection and who have well compensated liver function.

Status: Open to Accrual
Read More

GI16-263

Study Title: A phase II multi-center study evaluating combination immunotherapy for advanced cholangiocarcinoma with pembrolizumab and Sylatron (peginterferon alfa-2b) HCRN GI16-263

Status: Open to Accrual
Read More

GU14-182

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer: HCRN GU14-182

Status: Open to Accrual
Read More

GU14-188

Phase Ib/II Study of Neoadjuvant Pembrolizumab With Gemcitabine-Cisplatin (Cisplatin-Eligible) or Gemcitabine (Cisplatin-Ineligible) in Subjects With T2-4aN0M0 Urothelial Cancer: HCRN GU14-188

Status: Open to Accrual
Read More

GU15-215

Study Title: A Randomized Phase II Trial of Atezolizumab with or without Bevacizumab in Cisplatin-ineligible Patients with Advanced/Unresectable Urothelial Cancer

Status: Open to Accrual
Read More

GU15-217

Study Title: UC-GENOME: Urothelial Cancer-GENOmic Analysis to iMprove Patient Outcomes and rEsearch: Hoosier Cancer Research Network GU15-217

Status: Open to Accrual
Read More

GU15-223

Randomized Phase II trial comparing sequential first-line sunitinib and second-line avelumab versus first-line avelumab and second-line sunitinib for metastatic renal cell carcinoma: SUAVE trial: HCRN GU15-223

Status: Open to Accrual
Read More

GU16-243

Study Title: PhAse I/II StuDy of Modern ImmunotherApy in BCG-RelaPsing UroThelial Carcinoma of the BLADDER – (ADAPT-BLADDER) HCRN GU16-243

Status: Open to Accrual
Read More

GU16-260

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Status: Open to Accrual
Read More

LUN13-175

A Phase I/II Study of Carboplatin/Nab-Paclitaxel and MK-3475 for Advanced Non-Small Cell Lung Cancer (NSCLC): HCRN LUN13-175

Status: Open to Accrual
Read More

LUN15-233

Randomized Phase II Trial of Docetaxel plus Nivolumab or Docetaxel alone in patients with advanced non-squamous NSCLC and previous clinical benefit on treatment with single agent Nivolumab.

Status: Open to Accrual
Read More

MEL16-252

Study Title: Single Arm Phase II Study of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma (SALVO Study). HCRN: MEL16-252

Status: Open to Accrual
Read More

TBCRC035

Palbociclib in Combination with Fulvestrant or Tamoxifen as Treatment for Hormone Receptor Positive Metastatic Breast Cancer with Prior Chemotherapy for Advanced Disease: A Phase II study with Pharmacodynamics Markers (TBCRC035)

Status: Open to Accrual
Read More

TBCRC044

Study Title: A Randomized Phase II Study of Pembrolizumab, an Anti-PD (Programmed Cell Death)-1 Antibody, in Combination With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease

Status: Open to Accrual
Read More

BRE09-146

PARP Inhibition After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer or ER/PR +, HER2 Negative With Known BRCA1/2 Mutations: Hoosier Oncology Group BRE09-146

Status: Closed to Accrual
Read More

GI12-162

A Randomized Phase II Study of Dual Epidermal Growth Factor Receptor Inhibition with Erlotinib and Panitumumab With or Without Irinotecan as Second Line Therapy in Patients with Metastatic Colorectal Cancer.

Status: Closed to Accrual
Read More

GI14-186

A Multi-Center, Single Arm, Phase II study of Pembrolizumab (MK-3475) in Combination with Chemotherapy for Patients with Advanced Colorectal Cancer: HCRN GI14-186

Status: Closed to Accrual
Read More

GI14-191

A Randomized Phase II Trial to Evaluate the Efficacy of Supportive Therapy with Ginseng for Patients on Treatment with Regorafenib: HCRN GI14-191.

Status: Closed to Accrual
Read More

More Trials →